Research Article

Single-center Experience in Relapsed / REFRACTORY NON-HODGKIN’S lymphoma

Volume: 44 Number: 1 March 30, 2022
Cumhuriyet Medical Journal Cover
Cumhuriyet Medical Journal
PDF Download
EN

Single-center Experience in Relapsed / REFRACTORY NON-HODGKIN’S lymphoma

Abstract

Non-Hodgkin’s lymphomas are a heterogeneous malignancy group originating from lymphoid tissue and having an increasing frequency in the world in the last decade. Its clinic and response to treatment vary according to different sub-types. Today, the most compelling situation for a clinician is the patients with relapsed or refractory Non-Hodgkin’s lymphoma. Its prognosis is poor even despite different treatments and autologous stem cell transplantation. The aim of the present study is to present the experiences in the diagnosis of relapsed/refractory Non-Hodgkin’s lymphoma to the literature. A total of 193 patients, who were diagnosed and treated at Sivas Cumhuriyet University Medical Faculty Hospital between 2011 and 2021 were included in the study. 145 of these patients were not relapsed/refractory and 48 were relapsed/refractory. Rescue therapy was provided to the relapsed/refractory patients; however, autologous stem cell transplantation could only be applied to 25 patients. Of the stem cell transplantation patients, 17 are still alive. As a result, the best treatment under current conditions is the rescue therapy, followed by autologous stem cell transplantation. However, relapsed/refractory Non-Hodgkin’s lymphomas have a quite poor prognosis; thus, new treatment agents are required.

Keywords

References

  1. 1. Howlader N, Morton LM, Feuer EJ, Besson C, Engels EA. Contributions of Subtypes of Non-Hodgkin Lymphoma to Mortality Trends. Cancer Epidemiol Biomarkers Prev 2016; 25(1): 174–179.
  2. 2. Moubadder L, McCullough LE, Flowers CR, Koff JL. Linking Environmental Exposures to Molecular Pathogenesis in Non-Hodgkin Lymphoma Subtypes. Cancer Epidemiol Biomarkers Prev. 2020; 29(10): 1844–1855. doi: 10.1158/1055-9965.EPI-20-0228.
  3. 3. Younes A, Salles G, Martinelli G, Bociek RG, Barrigon DC, Barca EG, et al. Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma. Haematologica 2017; 102(12): 2104–2112. doi: 10.3324/haematol.2017.169656.
  4. 4. Shipp MA, Harrington DP, Anderson JR, Armitage JO, Bonadonna G, Brittinger G. International Non-Hodgkin’s Lymphoma Prognostic factors Project. A Predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med1993; 329: 987-994.
  5. 5. Schmıtt M, Trenschel R, Sayer HG, Schneıder C, Glass A, Hılgendorf I, et al. Conditioning with treosulfan and fludarabine for patients with refractory or relapsed non‑Hodgkin lymphoma. Molecular and Clınıcal Oncology 2013; 2: 773-782.
  6. 6. Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-Hodgkin lymphoma. The lancet 2017; 390(10091):298-310. doi: 10.1016/S0140-6736(16)32407-2
  7. 7. Demir D, Özsan N, Demir E, Arslan A, Davulcu EA, Soyer NA, et al. Retrospective evaluation of the epidemiological and overall survival characteristics of adult non-Hodgkin lymphoma cases registered to Ege University Hospital database Ege Tıp Dergisi / Ege Journal of Medicine 2020; 59: Ek Sayı /Supplement 66-78.
  8. 8. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision to the World Health Organization classification of lymphoid neoplasm. Blood 2016; 127, 2375–2390.

Details

Primary Language

English

Subjects

Health Care Administration

Journal Section

Research Article

Authors

Publication Date

March 30, 2022

Submission Date

February 28, 2022

Acceptance Date

March 24, 2022

Published in Issue

Year 2022 Volume: 44 Number: 1

DOI

https://doi.org/10.7197/cmj.1079526

IZ

https://izlik.org/JA55BF72MT

Cite

RIS / Bibtex
AMA
1.Terzi H, Oral K, Yılmaz H, Demir Yurtseven E, Şencan M. Single-center Experience in Relapsed / REFRACTORY NON-HODGKIN’S lymphoma. CMJ. 2022;44(1):51-56. doi:10.7197/cmj.1079526